Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ALPL | P05186 | 1/20 | 0.42 |
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | ALPG | P10696 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21938147 | 0.86 | GRM4 (0.43) | MAPTGAAKDM4EKMT2AHDAC1 | |
| SCHEMBL9936655 | 0.83 | KDM4E (0.61) | MAPTGAAKDM4EMEN1KMT2A | |
| SCHEMBL21937973 | 0.80 | MEN1 (0.57) | MAPTGAAKDM4EMEN1KMT2A | |
| SCHEMBL21937974 | 0.78 | PTPN1 (0.52) | MAPTGAAKDM4EKMT2AHTT | |
| SCHEMBL21938207 | 0.78 | RXFP1 (0.39) | MAPTGAAKDM4EMEN1KMT2A | |
| SCHEMBL1785693 | 0.76 | GAA (0.51) | MAPTGAAKDM4EMEN1KMT2A | |
| SCHEMBL1942975 | 0.76 | DHPS (0.61) | MAPTGAAKDM4EHTTALDH1A1 | |
| SCHEMBL21938148 | 0.76 | KMT2A (0.56) | MAPTGAAKDM4EMEN1KMT2A | |
| SCHEMBL1941087 | 0.73 | PTGS1 (0.58) | MAPTGAAKDM4EHTTCYP1A2 | |
| SCHEMBL1941422 | 0.72 | ALDH1A1 (0.46) | MAPTGAAKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210379077-A1 | TOPOISOMERASE II CATALYTIC INHIBITOR COMPOUND THERAPEUTICS FOR CANCER TREATMENT, METHODS AND USES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2021-12-09 | — | — | US | disclosed |
| WO-2020077437-A1 | TOPOISOMERASE II CATALYTIC INHIBITOR COMPOUND THERAPEUTICS FOR CANCER TREATMENT, METHODS AND USES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210379077-A1 | TOPOISOMERASE II CATALYTIC INHIBITOR COMPOUND THERAPEUTICS FOR CANCER TREATMENT, METHODS AND USES | TOP2A, TOP2B, TOP1 | MAPT 3670/4885GAA 175/4885KDM4E 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.